Table 3.
Prognostic Factors for Overall Survival and Progression-Free Survival After PSM (n=58)
| Overall Survival | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (<53 vs ≥53 years) | 0.914 | 0.411–2.032 | 0.825 | 1.449 | 0.614–3.420 | 0.507 |
| Control of the primary liver lesion (CR/PR vs PD) | 1.633 | 0.747–3.568 | 0.219 | 0.836 | 0.358–1.951 | 0.615 |
| Liver cirrhosis (yes or no) | 0.644 | 0.326–1.272 | 0.205 | 0.517 | 0.226–1.187 | 0.428 |
| Application of local therapy for metastatic lesions | 3.563 | 1.734–7.322 | 0.001 | 3.574 | 1.703–7.502 | 0.001 |
| AFP (<400 vs ≥400 ng/mL) | 4.027 | 1.969–8.237 | <0.001 | 4.366 | 2.058–9.265 | <0.001 |
| PIVKA II (<200 vs ≥200 mAU/mL) | 0.918 | 0.456–1.849 | 0.812 | 0.441 | 0.189–1.031 | 0.157 |
| Progression-Free Survival | Univariate Analysis | Multivariate Analysis | ||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (<53 vs ≥53 years) | 0.622 | 0.282–1.374 | 0.240 | 0.627 | 0.104–3.764 | 0.233 |
| Control of the primary liver lesion (CR/PR vs PD) | 1.149 | 0.534–2.471 | 0.722 | 0.629 | 0.085–4.659 | 0.864 |
| Liver cirrhosis (yes or no) | 0.647 | 0.329–1.274 | 0.208 | 0.897 | 0.243–3.312 | 0.902 |
| Application of local therapy for metastatic lesions | 2.531 | 1.290–4.964 | 0.007 | 3.992 | 1.266–12.595 | 0.018 |
| AFP (<400 vs ≥400 ng/mL) | 2.806 | 1.368–5.758 | 0.005 | 2.243 | 1.055–4.767 | 0.036 |
| PIVKA II (<200 vs ≥200 mAU/mL) | 1.104 | 0.549–2.223 | 0.781 | 0.318 | 0.048–2.086 | 0.954 |
Abbreviations: PSM, propensity score matching; CR, complete response; PR, partial response; PD, progressive disease; AFP, alpha-fetoprotein; PIVKA-II, protein induced by Vitamin K absence of antagonist II; HR, hazard ratio; CI, confidence interval.